TransMedics (TMDX) Research & Development (2018 - 2026)

TransMedics' Research & Development history runs 9 years deep, the most recent figure standing at $24.9 million for Q1 2026.

• On a quarterly basis, Research & Development rose 44.98% year-over-year to $24.9 million in Q1 2026; TTM through Mar 2026 was $76.8 million, a 24.33% increase from a year earlier, with the FY2025 full-year figure at $69.1 million, up 23.38% from the prior year.
• Research & Development grew to $24.9 million in Q1 2026 per TMDX's latest filing, from $20.7 million in the prior quarter.
• Across five years, Research & Development topped out at $24.9 million in Q1 2026 and bottomed at $5.8 million in Q4 2022.
• The 5-year median for Research & Development is $11.4 million (2024), against an average of $12.5 million.
• Across the five-year window, Research & Development dropped 22.07% in 2023 and soared 93.83% in 2024, its largest moves.
• Year by year, Research & Development stood at $5.8 million in 2022, then soared by 86.95% to $10.8 million in 2023, then jumped by 53.0% to $16.5 million in 2024, then climbed by 25.73% to $20.7 million in 2025, then gained by 20.18% to $24.9 million in 2026.
• Per Business Quant, the three latest TMDX Research & Development figures stand at $24.9 million (Q1 2026), $20.7 million (Q4 2025), and $15.3 million (Q3 2025).